The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

While you are soaking up the summer sun, doctors said you can still get sick, including from two new COVID strains that are going around.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.